List of Excipients in Branded Drug CLAFORAN

« Back to Dashboard

Claforan Excipient Strategy and Commercial Opportunities for Cefotaxime Sodium Injection

Last updated: October 9, 2026

Claforan is the former Sanofi brand for cefotaxime sodium, a parenteral third-generation cephalosporin. Its core patent and regulatory exclusivity have expired, leaving commercial value in generic supply, hospital-ready presentations, pediatric dosing, compatibility, stability, and dependable global distribution rather than in the original brand. The principal excipient is sodium carbonate, used to support the injectable formulation. The strongest product-development opportunities are low-excipient presentations, ready-to-use or extended-stability formats, differentiated vial sizes, and manufacturing platforms that improve supply reliability.

What is Claforan and what active ingredient does it contain?

Claforan contains cefotaxime sodium for injection. Cefotaxime is a beta-lactam antibacterial used for serious infections caused by susceptible gram-positive and gram-negative organisms, including lower respiratory tract, urinary tract, intra-abdominal, skin and soft-tissue, bone and joint, gynecologic, and bloodstream infections. It is also used in neonatal and pediatric settings under labeled clinical conditions.[1]

The product is administered intravenously or intramuscularly after reconstitution. Typical vial strengths include:

Product strength	Active ingredient	Primary use case
500 mg	Cefotaxime sodium equivalent to 500 mg cefotaxime	Pediatric and lower-dose hospital use
1 g	Cefotaxime sodium equivalent to 1 g cefotaxime	General inpatient use
2 g	Cefotaxime sodium equivalent to 2 g cefotaxime	Adult severe infection and high-dose regimens

The sodium content arises from both the cefotaxime sodium drug substance and the sodium carbonate formulation component. The precise sodium burden depends on the labeled product strength and formulation composition.[1]

What excipients are used in Claforan?

Claforan powder for injection uses sodium carbonate as the principal added excipient. The formulation is a sterile, lyophilized or dry powder presentation that is reconstituted before administration. The product does not rely on preservatives in the vial presentation described in the U.S. labeling.[1]

Claforan excipient profile

Component	Function	Commercial relevance
Cefotaxime sodium	Active pharmaceutical ingredient	Determines potency, antimicrobial spectrum, and stability burden
Sodium carbonate	Buffering and pH control; contributes to solubilization and formulation environment	Affects sodium load, reconstitution behavior, pH, and compatibility
Reconstitution diluent	Water for injection, sodium chloride, dextrose solutions, or other labeled compatible fluids	Determines administration flexibility and in-use stability
Container-closure system	Glass vial, stopper, seal, and labeling components	Controls moisture protection, sterility, extractables, and logistics

The commercially important distinction is between excipients present in the sterile powder and diluents added at the point of use. Sodium chloride and dextrose solutions may be authorized for reconstitution or infusion, but they are not necessarily ingredients in the unopened Claforan vial.[1]

Why is sodium carbonate used in cefotaxime injection?

Sodium carbonate provides an alkaline formulation environment suitable for cefotaxime sodium. It can improve the handling and dissolution characteristics of the dry product while helping maintain a formulation pH compatible with the active ingredient.

The excipient also creates product-development constraints:

1. It adds sodium to the administered dose.
2. It affects the final pH after reconstitution.
3. It can influence compatibility with other injectable drugs.
4. It must be controlled to avoid excessive alkalinity and degradation.
5. It affects the formulation's behavior in small-volume pediatric doses.

A generic developer should not treat sodium carbonate as a simple interchangeable filler. Its level, grade, residual water, particle characteristics, and interaction with cefotaxime sodium can affect assay, impurities, reconstitution time, solution clarity, and stability.

What excipient strategy is best for a generic Claforan product?

The preferred strategy is a minimal-excipient sterile powder formulation that closely matches the reference product's critical quality attributes. The development target should be pharmaceutical equivalence and therapeutic equivalence, not unnecessary excipient innovation.

Recommended formulation strategy

Development objective	Recommended approach
Minimize regulatory complexity	Use sodium carbonate or a functionally justified equivalent buffer system
Protect cefotaxime stability	Control moisture, oxygen exposure, pH, and thermal stress
Improve hospital usability	Optimize cake or powder structure for rapid, complete reconstitution
Reduce administration errors	Offer clear vial-strength differentiation and compatible diluent instructions
Address pediatric use	Provide 500 mg and 1 g strengths with low residual volume after reconstitution
Preserve supply flexibility	Qualify multiple API, vial, stopper, and diluent suppliers
Limit compatibility risk	Generate data for common infusion fluids and Y-site conditions

A formulation with fewer excipients generally has a cleaner regulatory narrative for an injectable generic. It also reduces the number of variables that must be matched against the reference product. A novel buffer system may create intellectual-property differentiation, but the commercial benefit is limited unless it delivers a measurable advantage in stability, administration, or container compatibility.

What formulations are protected by Claforan patents?

Claforan's original product protection is no longer a material commercial barrier in the United States. Cefotaxime was introduced decades ago, and the relevant composition, preparation, and product exclusivities expired long ago. Current generic entry is governed primarily by FDA abbreviated new drug application requirements, manufacturing compliance, sterile-product capability, and supply-chain execution.[2]

The strategic IP position is therefore:

IP category	Current relevance
Original cefotaxime composition patents	Expired
Original Claforan product patents	Expired or commercially immaterial
Basic sodium carbonate formulation claims	Unlikely to block ordinary generic entry
New ready-to-use or stabilized formulations	Potentially patentable if technically differentiated
Container-closure and delivery systems	Potentially patentable
Manufacturing process improvements	Potentially protectable as patents or trade secrets
Device or reconstitution systems	Potentially patentable
Brand and trade dress	Relevant only to branding and antitrust boundaries, not generic API entry

A company seeking differentiated protection could pursue claims directed to a specific cefotaxime concentration, stability profile, lyophilization cycle, reconstitution time, container system, or premixed presentation. Such claims would need to show technical performance beyond routine optimization.

When did Claforan lose exclusivity?

Claforan's U.S. market exclusivity ended decades ago. The product is not a modern patent-protected branded medicine, and cefotaxime sodium is available through generic regulatory pathways in multiple jurisdictions.

The key commercial milestones are:

Milestone	Status
Original FDA approval	Historical approval for cefotaxime sodium injection
Brand exclusivity	Expired
Core patent protection	Expired
Current U.S. pathway	ANDA-based generic entry under section 505(j)
Biosimilar pathway	Not applicable
Current competitive issue	Generic supply, quality, pricing, and contracting

FDA's Orange Book distinguishes approved products from discontinued products and lists patent and exclusivity information relevant to listed applications.[2] A Claforan-branded product may no longer be actively marketed in a particular jurisdiction even though cefotaxime generics remain approved and commercially available.

What is the FDA regulatory status of Claforan and cefotaxime?

Cefotaxime injection is regulated as a conventional small-molecule drug. Generic applicants generally use the ANDA pathway and must demonstrate pharmaceutical equivalence, bioequivalence where applicable, and compliance with current good manufacturing practice requirements.[3]

For a sterile injectable, the commercial burden is higher than the basic legal pathway suggests. FDA review focuses on:

• Sterility assurance
• Endotoxin control
• Particulate matter
• Container-closure integrity
• Assay and degradation products
• Reconstitution performance
• pH and osmolality
• Extractables and leachables
• Manufacturing process validation
• Stability under labeled storage conditions

Because cefotaxime is administered parenterally, a generic developer must establish that the proposed formulation and container system do not introduce clinically meaningful differences in administration or product quality.

Does cefotaxime have biosimilar risk?

No. Cefotaxime is a chemically synthesized small-molecule antibiotic, not a biologic. Biosimilar competition under the Public Health Service Act does not apply. The relevant competitive threat is generic cefotaxime sodium injection under the ANDA pathway.

This distinction matters commercially. A cefotaxime supplier does not need a biologics comparability package, but it does need a robust sterile manufacturing process and a reliable abbreviated application. Competition can emerge from multiple ANDA holders without the clinical-development costs associated with a new drug or biosimilar.

Are there Paragraph IV challenges involving Claforan?

Paragraph IV litigation is unlikely to be commercially significant for Claforan because the principal product and formulation protections expired long ago. A current cefotaxime ANDA applicant would generally face an expired-patent or no-blocking-patent environment rather than a litigation-centered launch strategy.

The relevant patent certifications may include:

• Paragraph I certification where no patent information is listed.
• Paragraph II certification where listed patents have expired.
• Paragraph III certification where a listed patent remains unexpired but the applicant will wait.
• Paragraph IV certification where the applicant asserts that a listed patent is invalid, unenforceable, or not infringed.

For a mature injectable antibiotic, the material risk is more often regulatory delay, manufacturing remediation, API supply interruption, or procurement exclusion than Paragraph IV litigation.

What commercial opportunities exist for cefotaxime excipient innovation?

The largest opportunities are operational products that reduce hospital preparation burdens or improve supply continuity.

1. Ready-to-use and premixed presentations

A ready-to-use or premixed cefotaxime product could reduce pharmacy compounding steps and preparation errors. The main technical obstacles are solution stability, concentration, microbial control, container compatibility, and shelf life.

Potential formats include:

• Flexible infusion bags
• Small-volume ready-to-administer containers
• Dual-chamber systems
• Pharmacy bulk packages
• Syringe-compatible presentations

A premixed product may obtain commercial differentiation even without strong patent protection if it offers a meaningful shelf-life or workflow advantage.

2. Improved reconstitution

A dry powder that dissolves rapidly with less foaming and lower particulate risk has practical hospital value. Reconstitution time, final volume, solution clarity, and low residual powder can support procurement differentiation.

Potential technical levers include:

• Controlled lyophilization cycle
• Particle engineering of cefotaxime sodium
• Optimized sodium carbonate level
• Vial headspace control
• Stopper and seal selection
• Improved powder cake geometry

3. Pediatric and neonatal formats

Pediatric hospitals need flexible strengths and predictable final concentrations. A 500 mg vial, low-volume reconstitution option, and clear dosing instructions can improve utilization. A formulation with lower total sodium contribution may have value in neonates and patients requiring sodium restriction, provided that it remains pharmaceutically equivalent and clinically appropriate.

4. Extended in-use stability

Hospitals increasingly value products that remain stable after reconstitution or dilution. A manufacturer that can support longer in-use windows under validated storage conditions may gain formulary and group-purchasing advantages.

The development package must address:

• Potency retention
• Degradation products
• Sterility and microbial risk
• pH drift
• Precipitation
• Container interaction
• Light exposure
• Infusion-line compatibility

5. Global-market presentations

Cefotaxime remains commercially relevant in markets where broad-spectrum injectable antibiotics are used in hospital settings and where ceftriaxone, cefepime, or other alternatives are less accessible or more expensive.

A global strategy should align:

• Vial sizes with local dosing practices
• Diluent availability with local hospital infrastructure
• Labeling with regional reconstitution standards
• Container systems with climatic-zone requirements
• Packaging with cold-chain and distribution conditions
• Registration strategy with WHO and national authority expectations

How does cefotaxime compare with competing injectable antibiotics?

Cefotaxime competes with ceftriaxone, ceftazidime, cefepime, and selected carbapenems. The most direct commercial comparator is ceftriaxone.

Attribute	Cefotaxime	Ceftriaxone
Generation	Third-generation cephalosporin	Third-generation cephalosporin
Administration	IV or IM	IV or IM
Dosing frequency	Often more frequent	Often once daily
Calcium-containing IV solution issue	Product-specific compatibility must be assessed	Major labeled restrictions in neonates
Commercial position	Mature generic injectable	Mature generic injectable with strong hospital penetration
Formulation opportunity	Reconstitution, pediatric dosing, premix	Premix, dual chamber, pediatric and outpatient formats
Primary competitive weakness	More frequent administration	Compatibility and calcium-related restrictions

Cefotaxime's dosing frequency can disadvantage it against ceftriaxone in outpatient and hospital workflow settings. Its commercial opportunity is stronger where clinicians value its established neonatal and inpatient use, where ceftriaxone's restrictions matter, or where procurement favors a lower-cost alternative.

Cefepime and carbapenems compete in more resistant infections but generally occupy different treatment positions. Stewardship programs may restrict broad-spectrum use, creating demand for products with reliable supply and clear susceptibility-based positioning.

What manufacturing and IP barriers affect commercial entry?

The principal barriers are technical and operational rather than patent-based.

Manufacturing barriers

• Sterile powder filling and lyophilization capability
• Control of moisture-sensitive cefotaxime sodium
• Validated aseptic processing
• Consistent reconstitution performance
• Container-closure integrity
• API impurity control
• Reliable vial and stopper supply
• Batch-release testing for sterility and endotoxins
• Stability data across intended climatic zones

IP and know-how barriers

• Optimized drying cycles
• API particle and bulk-density control
• Low-moisture packaging
• Premix stabilization
• Dual-chamber device engineering
• Compatibility data generated through proprietary testing
• Process controls maintained as trade secrets

A generic company does not need a broad patent estate to compete. It needs a reproducible sterile process, an approvable dossier, reliable API sourcing, and a purchasing strategy that can withstand hospital price pressure.

Which companies are challenging the Claforan commercial position?

The competitive field consists mainly of generic injectable manufacturers, contract manufacturers, and hospital-focused suppliers rather than branded innovators. Competition can arise from companies with:

• FDA-approved cefotaxime ANDAs
• European or national-market marketing authorizations
• Institutional injectable portfolios
• Government-procurement contracts
• Regional sterile manufacturing sites
• Ready-to-use antibiotic platforms

The relevant competitor set changes by country and procurement cycle. In the U.S., purchasing organizations and hospital systems often evaluate cefotaxime alongside ceftriaxone and other injectable cephalosporins based on price, back-order history, approved vial sizes, and contract reliability.

What revenue exposure does cefotaxime create?

Claforan itself has limited current revenue significance where the branded product has been discontinued or displaced by generics. The commercial value lies in the cefotaxime market rather than the Claforan trademark.

Revenue potential depends on:

1. Hospital and government tenders.
2. Injectable cephalosporin portfolio breadth.
3. Manufacturing cost per vial.
4. API procurement terms.
5. Ability to supply 500 mg, 1 g, and 2 g presentations.
6. Registration coverage across multiple countries.
7. Differentiated premix or ready-to-use products.
8. Shortage performance and contract reliability.

A commodity vial strategy can produce volume but usually faces severe price compression. A differentiated presentation can support better margins, but only if the hospital workflow benefit is clear and supported by stability and compatibility data.

What generic launch scenarios exist for cefotaxime?

Scenario 1: Commodity dry-powder vial

This is the lowest-risk development path. The product uses a conventional sterile powder formulation and competes on cost, quality, and availability. Margins are likely to be limited.

Scenario 2: Multi-strength hospital portfolio

Offering 500 mg, 1 g, and 2 g vials improves formulary coverage and simplifies hospital purchasing. This strategy is stronger than launching a single strength because it allows institutional contracts across pediatric and adult departments.

Scenario 3: Ready-to-use or premixed product

This strategy requires greater formulation and container investment but can create a defensible commercial position through convenience and reduced pharmacy preparation.

Scenario 4: Regional supply platform

A manufacturer can target markets with recurring injectable antibiotic shortages, local manufacturing incentives, or public procurement demand. The main advantage is supply reliability rather than patent exclusivity.

Key Takeaways

• Claforan is the former brand for cefotaxime sodium injection.
• Sodium carbonate is the principal added excipient in the conventional dry-powder formulation.
• Cefotaxime has no biosimilar pathway; competition is generic and ANDA-based.
• Original Claforan exclusivity and core patent protection have expired.
• Paragraph IV litigation is not the main commercial risk.
• The strongest opportunities are sterile supply reliability, rapid reconstitution, pediatric formats, premixed products, and extended in-use stability.
• Excipient innovation should focus on measurable performance, not unnecessary formulation complexity.
• Ceftriaxone is the closest commercial comparator, particularly because of its once-daily dosing advantage.
• Manufacturing capability, API quality, container closure, and procurement access are more important than legacy Claforan patent rights.
• A commodity cefotaxime vial is likely to face price pressure; a ready-to-use or workflow-oriented product has better differentiation potential.

FAQs About Claforan Excipient Strategy and Market Entry

Is sodium carbonate the only excipient in Claforan?

Sodium carbonate is the principal added excipient identified for the conventional Claforan sterile powder presentation. Reconstitution fluids are administered separately and should not automatically be treated as vial excipients.

Can a company patent a new cefotaxime formulation?

Yes. A new cefotaxime formulation may be patentable if it provides a non-obvious technical result, such as improved stability, longer in-use shelf life, faster reconstitution, or a novel delivery system.

Is cefotaxime still commercially attractive?

It can be attractive as part of a broader injectable antibiotic portfolio or as a differentiated hospital product. A standalone commodity vial is more exposed to price competition and procurement concentration.

Does cefotaxime require a biosimilar application?

No. Cefotaxime is a small-molecule drug. A conventional generic applicant generally uses the ANDA pathway in the United States.

What is the best commercial format for a new cefotaxime product?

The best format depends on the target market, but a multi-strength portfolio with a validated ready-to-use or extended-stability option offers stronger differentiation than a single conventional powder vial.

References

1. Sanofi-Aventis U.S. LLC. (n.d.). Claforan (cefotaxime sodium) for injection prescribing information. DailyMed, U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application (ANDA): Generics. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda/generic-drug-facts.